KR102226975B1 - 항-c5 항체 및 사용 방법 - Google Patents

항-c5 항체 및 사용 방법 Download PDF

Info

Publication number
KR102226975B1
KR102226975B1 KR1020187010179A KR20187010179A KR102226975B1 KR 102226975 B1 KR102226975 B1 KR 102226975B1 KR 1020187010179 A KR1020187010179 A KR 1020187010179A KR 20187010179 A KR20187010179 A KR 20187010179A KR 102226975 B1 KR102226975 B1 KR 102226975B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
acid sequence
hvr
Prior art date
Application number
KR1020187010179A
Other languages
English (en)
Korean (ko)
Other versions
KR20190009273A (ko
Inventor
요시나오 루이케
젠지로 삼페이
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20190009273A publication Critical patent/KR20190009273A/ko
Application granted granted Critical
Publication of KR102226975B1 publication Critical patent/KR102226975B1/ko

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187010179A 2016-06-17 2017-06-16 항-c5 항체 및 사용 방법 KR102226975B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016120325 2016-06-17
JPJP-P-2016-120325 2016-06-17
PCT/JP2017/022253 WO2017217524A1 (en) 2016-06-17 2017-06-16 Anti-c5 antibodies and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177020545A Division KR101852739B1 (ko) 2016-06-17 2017-06-16 항-c5 항체 및 사용 방법

Publications (2)

Publication Number Publication Date
KR20190009273A KR20190009273A (ko) 2019-01-28
KR102226975B1 true KR102226975B1 (ko) 2021-03-11

Family

ID=59969459

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187010179A KR102226975B1 (ko) 2016-06-17 2017-06-16 항-c5 항체 및 사용 방법
KR1020177020545A KR101852739B1 (ko) 2016-06-17 2017-06-16 항-c5 항체 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177020545A KR101852739B1 (ko) 2016-06-17 2017-06-16 항-c5 항체 및 사용 방법

Country Status (19)

Country Link
EP (1) EP3472316A4 (zh)
JP (3) JP6202774B1 (zh)
KR (2) KR102226975B1 (zh)
CN (3) CN115925922A (zh)
AU (1) AU2017285763B2 (zh)
BR (1) BR112018075688A2 (zh)
CA (1) CA3021956A1 (zh)
CL (1) CL2018003573A1 (zh)
CR (1) CR20190013A (zh)
EA (1) EA201990018A1 (zh)
IL (2) IL300611A (zh)
MX (2) MX2018015030A (zh)
MY (1) MY187848A (zh)
PE (2) PE20190394A1 (zh)
PH (1) PH12018502354A1 (zh)
SG (2) SG10201800265UA (zh)
TW (4) TWI610941B (zh)
UA (1) UA126561C2 (zh)
WO (1) WO2017217524A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
MY195714A (en) 2008-04-11 2023-02-07 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
HUE056489T2 (hu) 2014-12-19 2022-02-28 Chugai Pharmaceutical Co Ltd Anti-C5 antitestek és alkalmazási eljárások
MA45235A (fr) 2016-06-14 2019-04-17 Regeneron Pharma Anticorps anti-c5 et leurs utilisations
KR102226975B1 (ko) * 2016-06-17 2021-03-11 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 사용 방법
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
CN111278857A (zh) * 2017-10-04 2020-06-12 亚力兄制药公司 抗c5抗体治疗患有膜增生性肾小球肾炎的患者的剂量和施用
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
CA3111396A1 (en) * 2018-09-06 2020-03-12 The Trustees Of The University Of Pennsylvania Humanized anti-c5 antibodies and uses thereof
WO2020219922A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113834A2 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
WO2014028354A1 (en) * 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0230985Y2 (zh) 1985-07-08 1990-08-21
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ATE495618T1 (de) 2001-06-12 2011-01-15 Ericsson Telefon Ab L M Synchronisation in einem terrestrischen umts- funkzugriffsnetzwerk (utran)
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
JP4333939B2 (ja) 2001-08-27 2009-09-16 ロード・コーポレーション トロリ線の吊架装置
DE10253331A1 (de) 2002-11-14 2004-06-03 Symrise Gmbh & Co. Kg Verwendung von trans-Pellitori als Aromastoff
US7267849B2 (en) 2004-03-02 2007-09-11 Nitto Denko Corporation Compensator for liquid crystal display
KR20080069889A (ko) 2007-03-20 2008-07-29 (주)화도 폴리에틸렌 관
US8420298B2 (en) 2007-04-11 2013-04-16 Sekisui Chemical Co., Ltd. Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin
MY195714A (en) * 2008-04-11 2023-02-07 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly
PE20110225A1 (es) * 2008-08-05 2011-04-05 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
KR20100054403A (ko) 2008-11-14 2010-05-25 삼성전자주식회사 온라인 공동 작문 장치 및 방법
SG10201507722QA (en) * 2010-03-11 2015-10-29 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
KR20110111007A (ko) 2010-04-02 2011-10-10 이화여자대학교 산학협력단 L/d 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체
KR20110122011A (ko) 2010-05-03 2011-11-09 황보철종 매장 포인트 통합 관리 시스템 및 그 방법
EP2975055A4 (en) * 2013-01-31 2016-11-02 Univ Seoul Nat R & Db Found C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES
EP3473272A1 (en) * 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
HUE056489T2 (hu) * 2014-12-19 2022-02-28 Chugai Pharmaceutical Co Ltd Anti-C5 antitestek és alkalmazási eljárások
EP3390442B1 (en) * 2015-12-18 2023-11-08 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
KR102226975B1 (ko) * 2016-06-17 2021-03-11 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 사용 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113834A2 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
WO2014028354A1 (en) * 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics

Also Published As

Publication number Publication date
EP3472316A4 (en) 2020-01-08
JP6202774B1 (ja) 2017-09-27
SG10201800265UA (en) 2018-02-27
JP7032077B2 (ja) 2022-03-08
IL263657A (en) 2019-01-31
TW202239766A (zh) 2022-10-16
IL300611A (en) 2023-04-01
TWI789369B (zh) 2023-01-11
TW202337903A (zh) 2023-10-01
KR20190009273A (ko) 2019-01-28
JP2017226655A (ja) 2017-12-28
RU2019100222A (ru) 2020-07-17
MX2018015030A (es) 2019-04-22
TW201809000A (zh) 2018-03-16
UA126561C2 (uk) 2022-11-02
CN109312326A (zh) 2019-02-05
JP2022091748A (ja) 2022-06-21
CN109312326B (zh) 2022-09-09
RU2019100222A3 (zh) 2020-11-05
EA201990018A1 (ru) 2019-08-30
TW201808996A (zh) 2018-03-16
PE20190394A1 (es) 2019-03-13
CN115960223A (zh) 2023-04-14
CL2018003573A1 (es) 2019-02-01
MX2023001360A (es) 2023-02-27
WO2017217524A1 (en) 2017-12-21
KR101852739B1 (ko) 2018-04-30
PH12018502354A1 (en) 2019-09-23
PE20240825A1 (es) 2024-04-18
CR20190013A (es) 2019-03-05
EP3472316A1 (en) 2019-04-24
BR112018075688A2 (pt) 2019-04-02
TWI807666B (zh) 2023-07-01
AU2017285763A1 (en) 2018-11-08
SG11201705584VA (en) 2018-05-30
JP2018009021A (ja) 2018-01-18
MY187848A (en) 2021-10-26
AU2017285763B2 (en) 2024-02-01
CA3021956A1 (en) 2017-12-21
TWI610941B (zh) 2018-01-11
CN115925922A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
US11597760B2 (en) Method of detecting the presence of complement C5
KR102226975B1 (ko) 항-c5 항체 및 사용 방법
JP7208299B2 (ja) 抗c5抗体および使用方法
RU2789788C2 (ru) Антитела к с5 и способы их применения
EA041632B1 (ru) Антитела к с5 и способы их применения

Legal Events

Date Code Title Description
A107 Divisional application of patent
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant